poisar

Stock

Alnylam Pharmaceuticals, Inc. ALNY

$271.43+1.01%

Overview

ALNY market data

Price History

ALNY price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
65.49
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$2.33
Diluted earnings per share over the trailing twelve months.
Beta
0.25
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$266.43 – $495.55
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $37.8K · P/B 66.57 · P/S 8.82.

Company news

10 captured
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $400Benzinga · Jul 22, 2026, 2:44 PM
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200Globenewswire Inc · Jul 17, 2026, 1:15 PM
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines ExpandGlobenewswire Inc · Jul 15, 2026, 11:15 AM
Alnylam Highlights Neuroscience Progress At AAIC 2026, Initiating Phase 2 APPlauDS Study Of Mivelsiran In Down Syndrome-Associated Alzheimer's While Completing cAPPricorn-1 Enrollment In CAABenzinga · Jul 15, 2026, 7:48 AM
B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $410Benzinga · Jul 14, 2026, 1:42 PM
Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $410Benzinga · Jul 13, 2026, 4:07 PM
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $485Benzinga · Jul 13, 2026, 3:46 PM
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to GainBenzinga · Jul 10, 2026, 3:35 PM
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $400Benzinga · Jul 10, 2026, 1:50 PM
Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On ThursdayBenzinga · Jul 9, 2026, 2:05 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock